Chronic administration of phenytoin induces efflux transporter overexpression in rats

[1]  Cecilia Maldonado,et al.  Time-dependent and concentration -dependent upregulation of carbamazepine efflux transporter: a preliminary assessment from salivary drug monitoring , 2011 .

[2]  Caroline A. Lee,et al.  P-glycoprotein related drug interactions: clinical importance and a consideration of disease states , 2010, Expert opinion on drug metabolism & toxicology.

[3]  D. Goldstein,et al.  CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose , 2010, Journal of Pharmacology and Experimental Therapeutics.

[4]  H. Lennernäs,et al.  Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[5]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[6]  Xiao-dong Liu,et al.  Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain , 2008, Journal of the Neurological Sciences.

[7]  E. Aronica,et al.  Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier Affects Brain Uptake of Phenytoin in Epileptic Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[8]  C. D'Giano,et al.  Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences , 2006 .

[9]  T. Murakami,et al.  Expression and function of efflux drug transporters in the intestine. , 2006, Pharmacology & therapeutics.

[10]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[11]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[12]  M. Fromm,et al.  Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.

[13]  W. Löscher,et al.  Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[14]  W. Löscher,et al.  Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. , 2002, European journal of pharmacology.

[15]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[16]  M. Kuwano,et al.  [Multidrug resistance protein (MRP)]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[17]  Leslie Z. Benet,et al.  Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .

[18]  M. Hjelm,et al.  Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: Phenytoin , 1994, Epilepsy Research.

[19]  G. I. Rozova,et al.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. , 1992, British journal of clinical pharmacology.